secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001193125-24-018812
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO to merge with Tectonic in all-stock deal; $130.7M private financing; combined company targets GPCRs
--------------------------------------------------------------------------------

- Pre-merger AVRO holders expected to own ~22.3%; Tectonic holders ~40.2%; financing investors ~37.5% of combined firm.
- Concurrent $130.7M private placement from new and existing life sciences investors; combined cash ~$165M at close, runway into mid-2027.
- Combined company to advance Tectonic's lead asset TX45 (Fc-relaxin fusion protein) through clinical catalysts.
- AVRO stockholders to receive CVRs for contingent payments from future monetization of AVRO's legacy gene therapy assets.
- Support agreements from ~88% of Tectonic voting power and ~10.8% of AVRO shares; 180-day lock-up for insiders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524018812/0001193125-24-018812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524018812/d221662d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-018812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer